These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 17621382)

  • 1. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
    Rockwood K; Dai D; Mitnitski A
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of galantamine in patients with mild Alzheimer's disease.
    Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
    Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months.
    Wilkinson DG; Hock C; Farlow M; van Baelen B; Schwalen S
    Int J Clin Pract; 2002 Sep; 56(7):509-14. PubMed ID: 12296613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?
    Vellas B; Andrieu S; Cantet C; Dartigues JF; Gauthier S
    J Nutr Health Aging; 2007; 11(4):338-41. PubMed ID: 17653494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
    Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.
    Helmer C; Andrieu S; Pérès K; Orgogozo JM; Vellas B; Dartigues JF;
    Dement Geriatr Cogn Disord; 2007; 23(3):168-74. PubMed ID: 17215578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
    Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
    J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
    Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
    J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E; Onor ML; Saina M; Maso E
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
    Raskind MA; Peskind ER; Truyen L; Kershaw P; Damaraju CV
    Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
    Rockwood K; Fay S; Gorman M
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
    Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
    Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
    Wiig EH; Annas P; Basun H; Andreasen N; Lannfelt L; Zetterberg H; Blennow K; Minthon L
    Acta Neurol Scand; 2010 Mar; 121(3):186-93. PubMed ID: 19785641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.
    Rockwood K; Fay S; Song X; MacKnight C; Gorman M;
    CMAJ; 2006 Apr; 174(8):1099-105. PubMed ID: 16554498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
    Wallin AK; Andreasen N; Eriksson S; Båtsman S; Nasman B; Ekdahl A; Kilander L; Grut M; Rydén M; Wallin A; Jonsson M; Olofsson H; Londos E; Wattmo C; Eriksdotter Jonhagen M; Minthon L;
    Dement Geriatr Cogn Disord; 2007; 23(3):150-60. PubMed ID: 17312368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.
    Bullock R; Erkinjuntti T; Lilienfeld S;
    Dement Geriatr Cogn Disord; 2004; 17(1-2):29-34. PubMed ID: 14560062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verbal repetition in patients with Alzheimer's disease who receive donepezil.
    Asp E; Cloutier F; Fay S; Cook C; Robertson ML; Fisk J; Dei DW; Rockwood K
    Int J Geriatr Psychiatry; 2006 May; 21(5):426-31. PubMed ID: 16676290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline.
    Suh GH; Ju YS; Yeon BK; Shah A
    Int J Geriatr Psychiatry; 2004 Sep; 19(9):817-24. PubMed ID: 15352138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.